Published in Liver Transpl Surg on March 01, 1997
Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut (2002) 0.99
Management of occult hepatitis B virus infection: an update for the clinician. World J Gastroenterol (2011) 0.94
Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol (2006) 0.90
Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int (2010) 0.83
Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage? Transpl Int (2011) 0.82
Active vaccination to prevent de novo hepatitis B virus infection in liver transplantation. World J Gastroenterol (2015) 0.79
De novo hepatitis B virus infection developing after liver transplantation using a graft positive for hepatitis B core antibody. Ann Surg Treat Res (2015) 0.78
Selecting suitable solid organ transplant donors: Reducing the risk of donor-transmitted infections. World J Transplant (2014) 0.78
Adult Living Donor Liver Transplantation Using Hepatitis B Core Antibody-Positive Grafts in Korea, a Hepatitis B-endemic Region. Gut Liver (2011) 0.77
Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers. Hepatol Int (2011) 0.76
Kinetics of phytohemaglutinin-induced IFN-gamma and TNF-alpha expression in peripheral blood mononuclear cells from patients with chronic hepatitis B after liver transplantation. World J Gastroenterol (2005) 0.76
Hepatitis B virus infection in liver transplant candidates and recipients. MedGenMed (2005) 0.75
Hard times and imperfect organs. Liver Transpl Surg (1997) 0.75
Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation. World J Hepatol (2015) 0.75
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology (1990) 4.02
MELD and PELD: application of survival models to liver allocation. Liver Transpl (2001) 3.76
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74
Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology (1980) 3.57
Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med (1996) 3.38
"Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet (1994) 3.33
Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A (1999) 3.30
Molecular virology and pathogenesis of hepatitis B. Lancet (1993) 3.27
Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA (1999) 2.78
A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol (1997) 2.65
HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol (2000) 2.60
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ann Intern Med (1997) 2.38
Current concepts. Primary sclerosing cholangitis. N Engl J Med (1984) 2.35
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl (2000) 2.27
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology (1989) 2.19
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology (1994) 2.10
Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1991) 2.06
Intrapulmonary vascular dilatations (IPVD) in liver transplant candidates. Screening by two-dimensional contrast-enhanced echocardiography. Chest (1990) 1.99
Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med (1987) 1.98
Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94
Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc (1989) 1.93
Gastrointestinal Kaposi's sarcoma in patients with acquired immunodeficiency syndrome. Endoscopic and autopsy findings. Gastroenterology (1985) 1.90
Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl (2000) 1.88
Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology (1982) 1.88
Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant (2008) 1.86
Acute hepatitis C. Hepatology (2001) 1.82
Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg (1991) 1.78
Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology (1990) 1.76
A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients. J Infect Dis (1995) 1.71
Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients. Mayo Clin Proc (1988) 1.71
Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology (1990) 1.69
Detection of cytomegalovirus DNA in sera of liver transplant recipients. J Clin Microbiol (1994) 1.69
The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation (1995) 1.67
Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis (2000) 1.66
Complications and risk factors after ileal pouch-anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis. Ann Surg (1993) 1.63
Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology (1996) 1.62
Choledochocholedochostomy, a relatively safe procedure in orthotopic liver transplantation. Surgery (1985) 1.61
Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc (1993) 1.59
Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc (1994) 1.59
Clinical and radiologic features of cerebral edema in fulminant hepatic failure. Mayo Clin Proc (1995) 1.59
De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant (2014) 1.57
Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc (1990) 1.56
Liver transplantation for Wilson's disease: a single-center experience. Liver Transpl Surg (1999) 1.55
Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med (2001) 1.55
A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet (1995) 1.54
Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology (1997) 1.54
Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology (1993) 1.53
Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. Gut (2003) 1.51
Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology (1992) 1.51
Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology (1983) 1.49
Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative-strand viral RNA in various tissues. Hepatology (1998) 1.49
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 1.49
Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery. Anesthesiology (1999) 1.49
Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study. Liver Transpl (2001) 1.48
Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology (1999) 1.48
The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology (1996) 1.48
Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol (1997) 1.47
Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology (1998) 1.46
Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology (1992) 1.46
Nitric oxide-induced mutations in the HPRT gene of human lymphoblastoid TK6 cells and in Salmonella typhimurium. Environ Mol Mutagen (2000) 1.46
Are HCV-infected individuals candidates for hepatitis A vaccine? Lancet (1998) 1.46
Characterization of non-transferrin-bound iron clearance by rat liver. J Biol Chem (1986) 1.46
A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc (2000) 1.45
Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation (1996) 1.44
Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis. Mayo Clin Proc (1991) 1.44
The autologous mixed lymphocyte reaction in primary biliary cirrhosis: analysis of activation and blastogenesis of autoreactive T lymphocytes. Hepatology (1988) 1.43
Retracted Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy. Gastroenterology (1992) 1.43
Orthotopic liver transplantation for preoperative early-stage hepatocellular carcinoma. Mayo Clin Proc (1994) 1.43
Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology (1986) 1.43
The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg (1998) 1.42
Nutritional support for liver transplantation: identifying caloric and protein requirements. Mayo Clin Proc (1994) 1.42
Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology (1992) 1.41
The role of portosystemic shunts for variceal bleeding in the liver transplantation era. Arch Surg (1994) 1.40
Hepatitis C and liver transplantation. J Hepatol (2001) 1.40
Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol (2000) 1.40
Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis (1995) 1.39
Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc (1990) 1.39